Boston Scientific Shoots For Cardiac Ablation Leadership With $387M Farapulse Acquisition
Boston Scientific will exercise its option to buy the remaining 73% of Farapulse, the first company to market a pulsed field cardiac ablation system.
Boston Scientific will exercise its option to buy the remaining 73% of Farapulse, the first company to market a pulsed field cardiac ablation system.